Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge assists in connection with the acquisition of Alergovet S.L.
Mandate

Vinge assists in connection with the acquisition of Alergovet S.L.

December 14, 2016

Vinge assists Nextmune Holding B.V., primarily owned by Fidelio Capital and Premune, in connection with the acquisition of the shares in Alergovet S.L. Alergovet is a leading company in Southern Europe focused on the diagnoses and treatment of atopic dermatitis for companion animals and horses, and offers high quality allergy tests and allergen-specific immunotherapy treatment for companion animals and horses.

Vinge’s team consists of partner Jonas Johansson together with, among others, associates Albert Wållgren, Linn Adelwald, Isabell Nielsen, Andréa Nicolin, Gustav Tengblad and Sofia Bergenstråhle.

Related

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.
October 22, 2024

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its directed share issue

 Vinge has advised Vicore Pharma Holding AB (publ) in connection with a directed share issue, whereby Vicore receives issue proceeds of approximately SEK 100 million before deduction of transaction costs.
October 22, 2024

Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS

 Vinge has advised the Swedish state in connection with the reconstruction proceedings of SAS. The proceedings, which included considerations regarding state aid approved by the European Commission, have among other things involved restructuring, debt write-downs as well as an investment by a consortium consisting of Castlelake, Air France-KLM, Lind Invest and the Danish state. In total, the investment amounted to approximately USD 1.2 billion in SAS, divided into USD 475 million in unlisted equity and USD 725 million in convertible debt.
October 21, 2024